NASDAQ$GDRX
GoodRx Holdings Inc. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fourth quarter and full year 2023 results, showing revenue and adjusted revenue increased by 7% to $196.6 million, driven by prescription transactions.
GoodRx's Q4 2023 results showed a 7% increase in revenue and adjusted revenue to $196.6 million. The company reported a net loss of $25.9 million, while adjusted EBITDA reached $57.3 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.
- Revenue and Adjusted Revenue increased 7% to $196.6 million.
- Net loss was $25.9 million, with a net loss margin of 13.2%.
- Adjusted EBITDA was $57.3 million, resulting in an Adjusted EBITDA Margin of 29.1%.
- The company repurchased $77.8 million in shares of Class A common stock.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$197M
Revenue by segment
GoodRx · $175M total across 3 segments · Q3 2023
- Prescription Transactions$135M+3.2%77.6%
- Subscription$23.2M-12.5%13.3%
- Pharma Direct$15.9M-35.1%9.1%
Forward guidance
For Q1 2024, GoodRx anticipates revenue and Adjusted Revenue between $195 million and $198 million, with an Adjusted EBITDA Margin in the high twenty-percent range, potentially up to 30%. For the full year 2024, the company expects revenue and Adjusted Revenue to be approximately $800 million and Adjusted EBITDA of approximately $250 million.
Tailwinds
- First quarter revenue and Adjusted Revenue are expected to grow by 6% to 8% year-over-year.
- Adjusted EBITDA Margin is expected to be in the high twenty-percent range, potentially up to 30% for the first quarter.
- Full year revenue and Adjusted Revenue are projected to be around $800 million.
- Adjusted EBITDA for the full year is expected to be approximately $250 million.
- Balance sheet and liquidity position remained strong.
Headwinds
- Full year growth rates are tempered by the approximately $25 million topline impact associated with pharma manufacturer solutions restructuring.
- Consumer incentives are expected to reduce revenue.
- Anticipated sunset of the Kroger Savings Club will impact revenue.
- Recent system outages disclosed by UnitedHealth Group may have an impact on financials.
- The company reported a net loss of $25.9 million in Q4 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro